Evaluations of the Performance of the Aβ42/Aβ40 Ratios, p-Tau181 and p-Tau217 Assays in Alzheimer’s Disease Plasma (P7-9.002)

We have evaluated the recently developed blood-based Fujirebio Lumipulse Aβ42/Aβ40 ratios, p-Tau181, and the Quanterix/Simoa AlZPath p-Tau217 assays in AD subjects (n=63) and healthy controls (n= 24), to characterize the discriminatory and correlative relationships for each assay within and between clinical diagnosis groupings